Sponsor Directory

AstraZeneca clinical trials

Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1904

Shown on this page

Current sort

Live official records

Open in full search

Conditions: RSV Respiratory Syncytial Virus
Interventions: AZD6489, Licensed RSV vaccine #1, Licensed RSV vaccine #2; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 60 Years and older
Enrollment: 164 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 3 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 40
States / cities: Huntsville, Alabama • Mobile, Alabama • Sheffield, Alabama + 36 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Elecoglipron, Dapagliflozin, Elecoglipron-matched placebo, Dapagliflozin-matched placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 27
States / cities: Birmingham, Alabama • Daphne, Alabama • Lomita, California + 24 more

Conditions: COVID-19, SARS-CoV-2 Infection
Interventions: AZD9838, Licensed SARS-CoV-2 mRNA vaccine, AZD6563; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 2 more

Conditions: Gastric Cancer
Interventions: Fluorouracil (5-FU), Capecitabine, Durvalumab, Oxaliplatin, Trastuzumab, Trastuzumab deruxtecan, Cisplatin, Pembrolizumab, Volrustomig, Rilvegostomig; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 4
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Durvalumab, Domvanalimab, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 791 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 32
States / cities: Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 28 more

Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: Not listed
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2028
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Boston, Massachusetts + 5 more

Conditions: Healthy Participants
Interventions: Elecoglipron, Atorvastatin, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Asthma
Interventions: Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 22
States / cities: Encinitas, California • Lancaster, California • Los Angeles, California + 19 more

Conditions: Advanced Solid Tumors That Are MTAP Deficient
Interventions: AZD3470, Datopotamab deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 8
States / cities: San Francisco, California • West Hollywood, California • New Haven, Connecticut + 5 more

Conditions: Non-small Cell Lung Cancer
Interventions: DS-1062a, Docetaxel; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Chandler, Arizona • Anaheim, California • Glendale, California + 28 more

Conditions: Transthyretin Amyloid Cardiomyopathy
Interventions: Not listed
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Palo Alto, California • Jacksonville, Florida • Chicago, Illinois + 3 more

About this AstraZeneca sponsor directory page

What this page lists: U.S. ClinicalTrials.gov public records where AstraZeneca is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within AstraZeneca trials.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.

AstraZeneca clinical trials

Filter and sort this sponsor

Live official records

A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

About this AstraZeneca sponsor directory page